The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects
Authors:
- 1 December 2005
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (12) , 1400-1406
Abstract
The pharmacokinetics of escitalopram (S‐citalopram) and its principal metabolite, S‐demethylcitalopram (S‐DCT), were investigated after intravenous and oral administration to healthy subjects. After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1100 L, respectively. After oral administration of single or multiple doses, the absorption was relatively fast, with the maximum observed plasma or serum concentration (Cmax) attained after 3 to 4 hours. The mean half‐lives were 27 and 33 hours, respectively; steady state was attained within 10 days. The area under the plasma or serum concentration‐time curve from time zero to 24 hours and Cmax was both linear and proportional to the dose. The apparent volume of distribution was around 20 L/kg. Comparison of the systemic and oral clearance implied a high absolute bioavailability. There was no evidence of interconversion from S‐citalopram to R‐citalopram either in plasma or in urine. Concurrent intake of food had no effect on the pharmacokinetics of escitalopram or its metabolite. All treatments were well tolerated.Keywords
This publication has 12 references indexed in Scilit:
- The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjectsBritish Journal of Clinical Pharmacology, 2005
- The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitorsEuropean Neuropsychopharmacology, 2005
- Efficacy of escitalopram in patients with severe depression: a pooled analysisInternational Journal Of Clinical Practice, 2005
- Escitalopram versus citalopram: the surprising role of the R-enantiomerPsychopharmacology, 2004
- Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesBritish Journal of Clinical Pharmacology, 2003
- EscitalopramCNS Drugs, 2003
- Escitalopram dose–response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depressionInternational Journal of Neuropsychopharmacology, 1999
- CitalopramCNS Drugs, 1997
- Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humansChirality, 1997
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992